title: CKD273, a new proteomics classifier assessing CKD and its prognosis.
abstract: National Kidney Foundation CKD staging has allowed uniformity in studies on CKD. However, early diagnosis and predicting progression to end stage renal disease are yet to be improved. Seventy six patients with different levels of CKD, including outpatients and dialysed patients were studied for transcriptome, metabolome and proteome description. High resolution urinary proteome analysis was blindly performed in the 53 non-anuric out of the 76 CKD patients. In addition to routine clinical parameters, CKD273, a urinary proteomics-based classifier and its peptides were quantified. The baseline values were analyzed with regard to the clinical parameters and the occurrence of death or renal death during follow-up (3.6 years) as the main outcome measurements. None of the patients with CKD273<0.55 required dialysis or died while all fifteen patients that reached an endpoint had a CKD273 score >0.55. Unsupervised clustering analysis of the CKD273 peptides separated the patients into two main groups differing in CKD associated parameters. Among the 273 biomarkers, peptides derived from serum proteins were relatively increased in patients with lower glomerular filtration rate, while collagen-derived peptides were relatively decreased (p<0.05; Spearman). CKD273 was different in the groups with different renal function (p<0.003). The CKD273 classifier separated CKD patients according to their renal function and informed on the likelihood of experiencing adverse outcome. Recently defined in a large population, CKD273 is the first proteomic-based classifier successfully tested for prognosis of CKD progression in an independent cohort.
authors.affiliation: RD Néphrologie, Montpellier, France.
authors.forename: Ángel
authors.initials: Á
authors.lastname: Argilés
authors.forename: Justyna
authors.initials: J
authors.lastname: Siwy
authors.forename: Flore
authors.initials: F
authors.lastname: Duranton
authors.forename: Nathalie
authors.initials: N
authors.lastname: Gayrard
authors.forename: Mohammed
authors.initials: M
authors.lastname: Dakna
authors.forename: Ulrika
authors.initials: U
authors.lastname: Lundin
authors.forename: Lourdes
authors.initials: L
authors.lastname: Osaba
authors.forename: Christian
authors.initials: C
authors.lastname: Delles
authors.forename: Georges
authors.initials: G
authors.lastname: Mourad
authors.forename: Klaus M
authors.initials: KM
authors.lastname: Weinberger
authors.forename: Harald
authors.initials: H
authors.lastname: Mischak
mesh_terms: D000368:Aged; D016000:Cluster Analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010455:Peptides / Q000652:urine; D011379:Prognosis; D040901:Proteomics / Q000379:methods*; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis* / Q000378:metabolism* / Q000652:urine; D015203:Reproducibility of Results
chemical_list: D010455:Peptides